서밋 테라퓨틱스 PLC(SMMT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $17.58 (-0.79%), 시가총액 $14.48B, 52주 최저~최고 $13.85 ~ $29.32.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. I
서밋 테라퓨틱스 PLC의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
서밋 테라퓨틱스 PLC의 현재 주가는 $17.58 (-0.79%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
서밋 테라퓨틱스 PLC의 시가총액은 약 $14.48B입니다.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead de